Oruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other analysts also recently commented on the stock. Wedbush raised their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. BTIG Research raised their target price on Oruka Therapeutics from $63.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Piper Sandler started coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $54.50.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $34.41 on Friday. The stock’s 50-day moving average is $32.26 and its 200 day moving average is $26.16. Oruka Therapeutics has a one year low of $5.49 and a one year high of $36.53. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -18.11 and a beta of -0.38.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares of the company’s stock, valued at approximately $1,101,162.66. This represents a 17.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 21,000 shares of company stock worth $663,530 over the last 90 days. 24.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. raised its position in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after buying an additional 788 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after buying an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the fourth quarter worth about $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.